Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract ...

Despite near universal availability of nirsevimab, only 35% of eligible children receive nirsevimab for RSV prophylaxis.

Professor Margie Danchin addresses declining childhood vaccination rates and vaccine hesitancy through trust-building ...

Pregnant individuals commonly reported hesitancy toward RSVpreF and nirsevimab, indicating the need for efforts to promote the safety and uptake of RSV immunization.

Shares in French pharma major Sanofi were 6% lower late Thursday after the presentation of the company’s second quarter ...

Nirsevimab showed 74.5% efficacy against medically attended lower respiratory tract infections caused by RSV in healthy infants in the trial compared to placebo.

A pooled analysis of data for AstraZeneca and Sanofi's respiratory syncytial virus (RSV) antibody nirsevimab has concluded that the drug is almost 80% effective at preventing lower respiratory ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Monoclonal antibodies (mAbs) have revolutionized medicine, providing innovative treatments for many diseases. For decades, ...

Babies born very prematurely will be offered protection against respiratory syncytial virus (RSV) with a long-acting antibody medicine. Nirsevimab provides protection with just one injection, ...

The Clinical Advisor spoke with Audrey M. Stevenson, PhD, MPH, MSN, FNP-BC, about how the changes to ACIP will affect vaccination recommendations moving forward. Dr Stevenson is a faculty member of ...

Vermont has the second lowest state fatality rate in the US (148.5 per 100K; Hawaii 113.8/100K). Mississippi (466.2/100K) and Oklahoma (461.5/100K) have the highest rates. The US average is 308.2/100K ...